OBJECTIVE: @entity356 is often diagnosed at an advanced stage and surgery alone cannot guarantee satisfactory results. Both chemoradiotherapy (CRT) and @entity7730 ( @entity7730 ) are used in postoperative therapy. However, it is controversial whether CRT or @entity7730 is better after D2 lymphadenectomy. In this study we investigated the efficacy of adjuvant CRT versus @entity7730 in @entity5 @entity1 treated with R0 gastrectomy and D2 lymph node dissection. @entity1 AND METHODS: Data from 92 @entity1 diagnosed with @entity356 and treated with surgery followed by adjuvant treatment were retrospectively analyzed. @entity1 were classified into two groups depending on type of adjuvant treatment such as @entity7730 (Arm A) and CRT (Arm B). RESULTS: Twenty-one @entity1 in Arm A and 71 @entity1 in Arm B were included. Median age at diagnosis was 60 years. The median follow-up time was 30 months. No difference in local recurrence (14.3 vs 15.7%, P = 0.89), peritoneal recurrence (29.4 vs 23.5%, P = 0.62), and distant metastases rates (57.1 vs 45.1%, P = 0.42) were observed between the arms. Disease-free survival (DFS) rates did not differ between Arms A and B (26 and 22 months, P = 0.80) respectively. Median overall survival (OS) in Arm A was 29 months and it was 32 months for Arm B. There was no difference in 5-year OS and DFS between Arms A and B (23.8 vs 34.4%, P = 0.74; and 24.1 vs 32.9%, P = 0.80). CONCLUSIONS: Adjuvant CRT does not appear to improve clinical outcomes compared to adjuvant @entity7730 in this study and prospective studies are required to confirm these results.

Adjuvant chemoradiation versus @entity7730 for XXXX after surgery with curative intent.

@entity5 :: ('MESH:D009369', 'Disease') :: ['stage III gastric cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma', 'Gastric cancer'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['CT', 'chemotherapy']
@entity5 :: (MESH:D009369,Disease) :: ['stage III gastric cancer']
